• (PLX AI) – Optomed shares rose 6% at the open after analysts at Kepler Cheuvreux upgraded the stock to buy from hold.
  • • Free cash flow should improve in the second half of the year as R&D expenses drop, while demand improves significantly, Kepler said
  • • Strong growth should continue in both of Optomed's segments as the pandemic effects subside and amid new product launches in 2023: Kepler
  • • Price target EUR 6.50 implies 78% upside

Quelle: PLX AI